<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633527</url>
  </required_header>
  <id_info>
    <org_study_id>812P202</org_study_id>
    <nct_id>NCT02633527</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SPN-812 ER in Children With ADHD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group,
      fixed dose study to assess the efficacy and safety of SPN-812 ER in treatment of children
      aged 6-12 years with ADHD. The primary objective is to assess the effect of SPN-812 ER in
      reducing ADHD symptoms. This will be measured using the ADHD-RS-IV rating scale.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">July 25, 2016</completion_date>
  <primary_completion_date type="Actual">July 25, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in ADHD symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change in ADHD symptoms will be evaluated as a change from baseline in the ADHD-RS-IV scale total score</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will be administered Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPN-810 ER Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will be administered low dose of SPN-812 ER</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPN-812 ER Low-Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will be administered low-medium dose of SPN-812 ER</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPN-812 ER High-Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will be administered high-medium dose of SPN-812 ER</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPN-812 ER High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will be administered high dose of SPN-812 ER</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-812 ER, Low Dose</intervention_name>
    <arm_group_label>SPN-810 ER Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-812 ER, Low-Medium Dose</intervention_name>
    <arm_group_label>SPN-812 ER Low-Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-812 ER, High-Medium Dose</intervention_name>
    <arm_group_label>SPN-812 ER High-Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-812 ER, High Dose</intervention_name>
    <arm_group_label>SPN-812 ER High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female subjects, 6-12 years of age, inclusive, with a diagnosis of
             ADHD according to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM
             IV), confirmed with the Mini International Neuropsychiatric Interview for Children and
             Adolescents (MINI-KID).

          2. ADHD-RS-IV-Parent Version: Investigator Administered and Scored score of at least 26.

          3. CGI-S score of at least 4

          4. Weight of at least 20 kg.

          5. Free of medication for the treatment of ADHD or any psychosis for at least one week
             prior to enrollment.

        Exclusion Criteria:

          1. Current or lifetime diagnosis of major depressive disorder, bipolar disorder,
             personality disorder, Tourette's disorder, or psychosis not otherwise specified.

          2. Currently meeting DSM-IV criteria for pervasive developmental disorder, obsessive
             compulsive disorder, post-traumatic stress disorder, or any other anxiety disorder as
             primary diagnosis.

          3. Significant systemic disease.

          4. Evidence of suicidality within the six months before Screening or at Screening.

          5. BMI greater than 95th percentile for the appropriate age and gender.

          6. Pregnancy or refusal to practice abstinence during the study for female subjects of
             childbearing potential (FOCP).

          7. Substance or alcohol use during the last three months.

          8. Positive urine screen for cotinine, alcohol, or drugs of abuse at Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

